Industry: Therapeutics for malignant gliomas
Abby Med has invented a novel class of cancer drugs targeting malignant gliomas, one of the leading causes of death from cancer.
The company’s molecules, called triphenylmethanes (TPMS), have shown to be effective against human glioma cell lines. TPMs are non-toxic and inexpensive to synthesize. Abby Med has developed a way to encapsulate TPMs for non-invasive delivery to patients.
A therapeutic agent based on TPMs could support surgical and chemotherapeutic treatments and improve survival outcomes in the 12,000 cases of glioma diagnosed in the U.S. each year.